EDINBURGH, Scotland and LONDON — September 10, 2025 — Leads & Copy — Resolution Therapeutics, a clinical-stage biopharmaceutical company, has appointed Lucy Singah as Chief Financial Officer (CFO) and Daniel Kennedy as Chief Business Officer (CBO). These appointments follow the announcement of the first patient dosed and safety cleared in its Phase I/II EMERALD study.
Dr. Amir Hefni, CEO of Resolution Therapeutics, expressed his excitement about welcoming Singah and Kennedy to the leadership team. He looks forward to working with the strengthened executive team to deliver on the company’s vision of transforming patient outcomes through regenerative macrophage therapy (RMT) in inflammatory and fibrotic diseases.
Lucy Singah brings over 20 years of corporate and strategic finance experience to Resolution Therapeutics. She joins from Echopoint Medical, where she served as CFO. Daniel Kennedy has over 20 years of experience building partnerships and leading licensing deals. Previously, he served as Vice President, Business Development at Immunocore plc (NASDAQ: IMCR) and held positions at Achillion Pharmaceuticals, Schering-Plough, and GSK.
Resolution Therapeutics is hosting an R&D Webinar on Wednesday, September 17, 2025, at 2pm BST / 9am ET / 6am PT alongside world-leading clinical hepatologists.
RTX001 is an engineered autologous regenerative macrophage therapy with enhanced anti-fibrotic and anti-inflammatory effects. The EMERALD Phase 1/2 study is now recruiting.
Contact:
[Contact information not provided in the press release]
Source: Resolution Therapeutics
